In addition to associations with ALL treatment-related hepatoxicity, UGT1A1 variants are associated with bilirubin level, and PNPLA3 variants are associated with ALT and AST levels within the general population at baseline.5,6,7 These findings suggest that genetic factors that influence healthy liver function can also have effects on drug-induced changes in liver function in patients with ALL. Here, GPT is linked to acute lymphoblastic leukemia.